Literature DB >> 26359434

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.

Efstathios Kastritis1, Maria Gavriatopoulou1, Marie-Christine Kyrtsonis2, Maria Roussou1, Evdoxia Hadjiharissi3, Argyris Symeonidis4, Panagiotis Repoussis5, Evridiki Michalis6, Sosana Delimpasi7, Konstantinos Tsatalas8, Panagiotis Tsirigotis9, Amalia Vassou10, Elina Vervessou11, Eirini Katodritou3, Dimitra Gika1, Evangelos Terpos1, Meletios A Dimopoulos1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26359434     DOI: 10.1182/blood-2015-05-647420

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  28 in total

Review 1.  Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.

Authors:  Jorge J Castillo; M Lia Palomba; Ranjana Advani; Steven P Treon
Journal:  Ther Adv Hematol       Date:  2016-06-13

Review 2.  Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 3.  Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

Authors:  Alexander Grunenberg; Christian Buske
Journal:  Dtsch Arztebl Int       Date:  2017-11-03       Impact factor: 5.594

Review 4.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

5.  Disease control should be the goal of therapy for WM patients.

Authors:  Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Blood Adv       Date:  2017-11-28

6.  What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.

Authors:  Steven P Treon; Jorge J Castillo
Journal:  Blood Adv       Date:  2017-11-28

Review 7.  Waldenström Macroglobulinemia: Review of Pathogenesis and Management.

Authors:  Seongseok Yun; Ariel C Johnson; Onyemaechi N Okolo; Stacy J Arnold; Ali McBride; Ling Zhang; Rachid C Baz; Faiz Anwer
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-03-07

Review 8.  Toward personalized treatment in Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 9.  Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.

Authors:  Prashant Kapoor; Jonas Paludo; Stephen M Ansell
Journal:  Curr Treat Options Oncol       Date:  2016-03

Review 10.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Authors:  Steven P Treon; Lian Xu; Maria Luisa Guerrera; Cristina Jimenez; Zachary R Hunter; Xia Liu; Maria Demos; Joshua Gustine; Gloria Chan; Manit Munshi; Nicholas Tsakmaklis; Jiaji G Chen; Amanda Kofides; Romanos Sklavenitis-Pistofidis; Mark Bustoros; Andrew Keezer; Kirsten Meid; Christopher J Patterson; Antonio Sacco; Aldo Roccaro; Andrew R Branagan; Guang Yang; Irene M Ghobrial; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.